BioSpace News Archive

Adial Pharmaceuticals, Inc. announced that it received notice from Nasdaq today that the Company has regained compliance with Nasdaq Listing Rule 5550, which requires listed companies to maintain stockholders’ equity of at least $2,500,000.

Cytokinetics, Incorporated announced five presentations at the 34th International Symposium on ALS/MND taking place in Basel, Switzerland and online from December 6, 2023 - December 8, 2023.

Xenon Pharmaceuticals Inc. announced that it has commenced an underwritten public offering of $225.0 million of its common shares and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, pursuant to its existing shelf registration statement.

By making slight modifications to an already approved brain stimulation technique called transcranial magnetic stimulation (TMS), researchers have reported profound improvement in patients with hard-to-treat depression.

Precigen, Inc. (Nasdaq: PGEN) today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 3:00 PM ET.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Monday, December 4, 2023, at 12:00pm PT / 3:00pm ET.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023.

Pasithea Therapeutics Corp. announced that its annual meeting of stockholders held on November 29, 2023 was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 26, 2023.

Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule).

Nanalysis Scientific Corp. (“the Company”) (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for industrial and research applications, releases its third quarter results ending September 30, 2023.